Scandinavian Candesartan Acute Stroke Trial "SCAST"

Recruiting

Phase N/A Results N/A

Summary of Purpose

To assess whether candesartan given to patients with elevated blood pressure in the acute phase of stroke is effective in reducing the risk of death or major disability at 6 months, and the risk of the combined event of vascular death, myocardial infarction, or stroke during the first 6 months.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 17 December 2010.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • Ullevaal University Hospital, Oslo, Norway. Norwegion authorities. AstraZeneca.

Trial Design

Randomized, placebo-controlled, double-blind, multi-center, international trial.

Contacts

  • Else Charlotte Sandset, MD Oslo, Norway E-mail: e.c.sandset@medisin.uio.no; Fax.: +4722119912; Tel.: +4723016660

    scast@scast.no